Organon & Co.
Organon & Co. (OGN) has a dated report snapshot, but its current priced-in claim is temporarily suppressed because the live engine record is unavailable or has changed.
• Organon is the women's-health and established-brands business Merck spun off in 2021, generating about $6.2 billion in revenue with the women's-health franchise contributing roughly $1.8 billion, but carrying the debt that came with the spinoff [Source: Organon 2025 results]. • The defining fact is the May 2025 dividend cut, from $1.12 to $0.08 per share, a near-elimination made to redirect roughly $345 million a quarter toward paying down nearly $9 billion of gross debt [Source: Organon 2025
Is OGN overvalued? See what's priced in →
589 institutional managers reported holding OGN in 13F filings for the quarter ended 2026-03-31. Together they hold about 76% of the company; the top 10 hold 44%. 67 opened new positions that quarter. Held by Vanguard Group, BlackRock, State Street, among others. On the short side, 19.0M shares were sold short as of the 2026-06-15 count, about 7% of shares outstanding (7.9 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
OGN's share count grew 2.7% over the past five years. It pays a dividend, and has paid one every year in our records (5 and counting); the current rate is $0.34 a share annually. Cash returned over the past three years: $537.00M in dividends.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at OGN over the trailing three years: 2024: 1 buy totaling $50k; 2025: 7 buys totaling $1.15M. 15 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
OGN's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-10 | +6.2% | -29.6% |
| 2023-11-04 | -9.3% | +8.5% |
| 2024-02-27 | +14.4% | +3.2% |
| 2024-05-04 | +4.1% | +2.3% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
OGN's latest 8-K filings: 2026-06-11 (items 5.02, 5.07, 9.01); 2026-04-30 (items 2.02, 9.01); 2026-04-27 (items 1.01, 5.02, 7.01, 9.01); 2026-02-20 (items 8.01, 9.01); 2026-02-12 (items 2.02, 7.01, 9.01).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.